Recent Company News

• 04:14 AM ET Aug 03, 2026
  

  StreetAccount Summary - Trading higher/lower: EU mid-morning

• 01:09 AM ET Sep 11, 2026
  

  Biophytis announces completion of €5.3M capital increase to fund its phase 2 trial in obesity (€0.07, 0.00)

• 01:12 AM ET Sep 09, 2026
  

  Biophytis expands OBA study to evaluate BIO101's potential to limit weight regain; regulatory protocol amendment filed in Brazil, with US and EU submissions to follow (€0.07, 0.00)

• 01:03 AM ET Aug 31, 2026
  

  Biophytis strengthens its financial position and extends its cash runway into Q1 of 2027 (€0.05, 0.00)

• 02:01 PM ET Aug 10, 2026
  

  StreetAccount Summary - Private Company Weekly Recap - Week of 3-Aug

• 01:18 AM ET Aug 10, 2026
  

  Biophytis receives approval from Brazil's National Health Surveillance Agency (ANVISA) to begin Phase 2 OBA clinical trial for obesity in Brazil (€0.03, 0.00)

• 01:06 AM ET Aug 03, 2026
  

  Biophytis provides an update on the rollout of its joint venture in Hong Kong; shares its short- and medium-term outlook (€0.01, 0.00)